VEA
SRNE

Virtus ETF Advisers’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Virtus ETF Advisers’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-125,062
Closed -$111K – 506
2022
Q4 		$111K Buy
125,062
+50,975
+69% +$67.6K 0.06% 435
2022
Q3 		$116K Buy
74,087
+540
+0.7% +$1.23K 0.05% 405
2022
Q2 		$148K Buy
73,547
+48,120
+189% +$83.2K 0.05% 321
2022
Q1 		$59K Sell
25,427
-1,501
-6% -$4.68K 0.03% 360
2021
Q4 		$125K Buy
26,928
+4,463
+20% +$27.7K 0.05% 368
2021
Q3 		$171K Sell
22,465
-1,181
-5% -$10K 0.08% 308
2021
Q2 		$229K Sell
23,646
-16,454
-41% -$131K 0.09% 246
2021
Q1 		$332K Buy
40,100
+713
+2% +$7.53K 0.14% 220
2020
Q4 		$269K Sell
39,387
-27,464
-41% -$221K 0.11% 283
2020
Q3 		$745K Sell
66,851
-9,133
-12% -$83.6K 0.39% 99
2020
Q2 		$477K Sell
75,984
-12,358
-14% -$47.3K 0.23% 155
2020
Q1 		$163K Sell
88,342
-12,874
-13% -$37.1K 0.07% 284
2019
Q4 		$342K Buy
101,216
+21,002
+26% +$50.1K 0.06% 285
2019
Q3 		$172K Sell
80,214
-4,468
-5% -$10.4K 0.03% 270
2019
Q2 		$226K Sell
84,682
-23,079
-21% -$83.1K 0.05% 281
2019
Q1 		$512K Sell
107,761
-16,062
-13% -$42.1K 1.09% 28
2018
Q4 		$297K Buy
123,823
+61,132
+98% +$200K 0.05% 114
2018
Q3 		$276K Sell
62,691
-46,025
-42% -$255K 0.03% 190
2018
Q2 		$783K Buy
+108,716
New +$740K 0.69% 42
2016
Q4 		– Sell
-40,438
Closed -$313K – 197
2016
Q3 		$313K Hold
40,438
– – 0.15% 96
2016
Q2 		$226K Buy
40,438
+4,308
+12% +$27.5K 0.17% 119
2016
Q1 		$194K Buy
+36,130
New +$210K 0.27% 90

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Virtus ETF Advisers's SRNE Position: Q1 2023 in Review

Virtus ETF Advisers sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 125,062 shares — an estimated $111K sold.

Virtus ETF Advisers first reported a position in SRNE in Q1 2016 and held it in 22 quarters. The position peaked at $783K in Q2 2018. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Virtus ETF Advisers reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 125,062 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $111K.
  • Virtus ETF Advisers first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 22 quarters.
  • Virtus ETF Advisers's Sorrento Therapeutics, Inc. position peaked at $783K in Q2 2018.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.